About Velabs Therapeutics Velabs Therapeutics, financed by Swiss-based Xlife Sciences Ltd., is a spin-off company launched by Europe's most renowned institute for life sciences research, the European Molecular Biology Laboratory (EMBL) and its technology transfer arm EMBLEM Technology Transfer GmbH (EMBLEM) EMBLEM, established in 1999, identifies, protects and commercializes the intellectual property developed in the EMBL world, from EMBL alumni and from non-EMBL third parties. EMBLEM currently manages a portfolio of more than 350 granted patents and patent applications, and has created 18 spin-out companies. EMBLEM facilitates and accelerates the transfer of innovative technology from basic research to industry by working closely with industrial partners spanning the biotech, IT and mechanical. To make this technology available to the scientific community, EMBL and its technology transfer arm, EMBLEM Technology Transfer (EMBLEM), created Luxendo as a spin-off company in 2015, with seed financing from EMBL Ventures and Life Science Partners (LSP). The spin-off's first two products, MuVi-SPIM and InVi-SPIM were launched in 2016
EMBLEM has a long history in successfully establishing spin-offs out of EMBL. Since its foundation, EMBLEM and EMBL have set-up 18 spin-off companies based on technologies invented/developed at the EMBL. We offer support with evaluating and developing the company concept and assistance with fund raising It was created as a spin-off company by EMBL and EMBL's technology transfer arm, EMBLEM, in 2015. The company launched the MuVi-SPIM and InVi-SPIM microscopes in 2016. Both microscopes avoid sample phototoxicity by sequentially illuminating a stack of small slices of the organism, allowing scientists to observe living organisms for extended periods of time without photodamage. The MuVi-SPIM microscope allows fast 3D imaging of living objects, such as spheroids and whole specimens without.
Facility established in 2004 as a collaboration between EMBL and German Cancer Research Center (DKFZ). 2006. Spin-off of Elara Pharmaceuticals GmbH out of the facility to develop dual inhibitors targeting tumors. 2009. Computational chemistry established. Spin-off of Savira GmbH to develop and commercialise screening derived hits targeting influenza virus Im Jahr 2000 wurde er Mitgründer und Wissenschaftlicher Direktor von Cellzome, dem erfolgreichsten Spin-off-Unternehmen aus dem EMBL. Heute gehört Cellzome zum Pharmakonzern GlaxoSmithKline. Der gebürtige Italiener Superti-Furga ist seit 2005 Wissenschaftlicher Direktor des Forschungszentrums für Molekulare Medizin der Österreichischen Akademie der Wissenschaften in Wien. Professor Kai. Established in late 2017, Velabs Therapeutics GmbH is EMBL's most recent spin-off project. The company uses a proprietary high-throughput screening platform based on a broad portfolio of novel EMBL microfluidics More information Visit websit
EMBL is Europe's flagship laboratory for the life sciences - an intergovernmental organisation with more than 80 independent research groups covering the spectrum of molecular biology. Research Bioinformatic ALPX is an EMBL spin-off, based at the European Photon Neutron campus in. Grenoble, France. It provides structural biology services and expertise. to pharmaceutical and biotech companies to accelerate. the drug discovery process EMBLEM has enjoyed continued success with these endeavours in 2019, including the incorporation of three spin-off companies and supporting EMBL in developing and expanding strategic partnerships with industry at various levels Bruker announced that it has acquired Luxendo, a privately held spin-off of the European Molecular Biology Laboratory (EMBL) that develops and manufactures proprietary light-sheet fluorescence microscopy instruments. Luxendo's proprietary single plane illumination microscopy (SPIM) technique significantly reduces sampling times over conventional laser scanning confocal microscopes, while reducing phototoxicity and damaging side effects on living specimens. This SPIM technology.
Cellzome, an EMBL spin-off company in the area of chemoproteomics, was acquired by GSK in 2012. EMBL-EBI and GSK, along with Biogen and the Wellcome Trust Sanger Institute, collaborate in Open Targets, an open innovation, public-private partnership with a focus on target selection and validation Velabs Therapeutics GmbH is a young spin-off of the EMBL (European Molecular Biology Laboratory) in Heidelberg and specializes in the rapid and functional screening of antibodies using droplet-based microfluidic technology. Compared to current antibody screening methods, Velabs' technology enables the quantitative and rapid recognition of antibody functions in target cells for the first time. EMBL spinoff to help antibody discovery. New EMBL spinoff company Velabs Therapeutics aims to speed up discovery of therapeutic 7 March 2018. By Iris Kruijen. Lab Matter EMBL spin-off company Luxendo has been acquired by Bruker Corporation. Based in Heidelberg, Germany, Luxendo develops and commercialises microscopes that use the Single Plane Illumination.
Velabs Therapeutics GmbH is a young spin-off of the EMBL (European Molecular Biology Laboratory) in Heidelberg and specialies in the rapid and functional screening of antibodies z using dropletbased microfluidic technology- . Compared to current methods of antibody screening, Velabs technology for the first time allows the quantitative and rapid recognition of antibody functions in target. Bruker today announced that it has acquired Luxendo, a privately held spin-off of the European Molecular Biology Laboratory (EMBL). Headquartered in Heidelberg, Germany, Luxendo was founded in September 2015. The company develops and manufactures proprietary light-sheet fluorescence microscopy instruments. Luxendo's proprietary single plane illumination microscopy (SPIM) technique. Der Proteomforscher und Systembiologe Superti-Furga war in den 1990er Jahren Forschungsgruppenleiter am EMBL gewesen. Im Jahr 2000 wurde er Mitgründer und Wissenschaftlicher Direktor von Cellzome, dem erfolgreichsten Spin-off-Unternehmen aus dem EMBL. Heute gehört Cellzome zum Pharmakonzern GlaxoSmithKline. Der gebürtige Italiener Superti-Furga ist seit 2005 Wissenschaftlicher Direktor des Forschungszentrums für Molekulare Medizin der Österreichischen Akademie der Wissenschaften in Wien Velabs Therapeutics GmbH ist ein Spin-off des European Molecular Biology Laboratory (EMBL) und seines Technologietransferarms EMBLEM Technology Transfer (EMBLEM). Das EMBL steht weltweit an der Spitze der Entwicklung und Anwendung von mikrofluidikbasierten Screening-Technologien. Die tröpfchenbasierte mikrofluidische Screening-Technologie des Unternehmens zielt auf die schnelle Generierung von Antikörpern gegen Signal-Proteine, die auf zellulären Membranoberflächen oder als lösliches. In March 2016, Evotec announced the formation of a spin-off company in the field of nanoparticle-based therapeutics to treat immunological disorders. Epidarex Capital, EMBL Ventures and Gimv participated together with Evotec in the EUR 14 m ($ 15.75 m) Series A round of Topas Therapeutics GmbH. Evotec will remain the largest shareholder after the financing round. The new company, Topas.
EMBL spin-off, Savira pharmaceuticals, collaborates with Roche in search for new drug-candidates Savira pharmaceuticals GmbH, a spin-off of the European Molecular Biology Laboratory (EMBL) based in Vienna, Austria, has signed a collaboration and license agreement with Roche, thus further strengthening the links between fundamental research and major pharmaceutical development companies EMBL Ventures was lead investor with LSP in October 2015 when Luxendo was created as a spin-off by the European Molecular Biology Laboratory (EMBL) and its technology transfer arm EMBLEM Technology Transfer (EMBLEM). Luxendo develops light-sheet microscopes for life science research using the proprietary Single Plane Illumination Microscopy (SPIM) technique developed at EMBL. The technology. Tobias joined EMBL as a PhD student in Heidelberg in 1998. After completing his doctorate, he joined EMBL spin-off, Anadys, before returning to EMBL a few years later to work as a research associate in Peer Bork's group, where he stayed until 2014. Tobias was an expert in protein domain identification and homology detection in sequence databases. Through countless collaborations, he used. EMBL spin-off company based in France, which uses. BM29 and MASSIF-1 are under way. The operation. EMBL technologies to provide structure-guided. of MASSIF-1 will be coordinated with HTX Lab. drug. The Annual Report is published once a year after having been approved by EMBL Council. It covers the past academic year and puts research at EMBL into a broad context of current molecular biology.
Fire Emblem is a fantasy tactical role-playing game franchise developed by Intelligent Systems and published by Nintendo.First produced and published for the Famicom in 1990, the series currently consists of seventeen core entries and three spinoffs. Gameplay revolves around the tactical movement of characters across grid-based environments, while incorporating a story and characters similar. EMBL scientists now show that in mice, there are actually two spindles, one for each set of parental chromosomes, meaning that the genetic information from each parent is kept apart throughout the first division. Science publishes the results - bound to change biology textbooks - on 12 July 2018. Artistic 3D rendering of the dual spindle in the mammalian zygote. IMAGE: Cartasiova/Hossain. EMBL spin-off BIOSAXS GmbH, during the next PIER Innovation Lunch Talk Join us for a get-together after the talk, discuss further questions with the speaker and meet like-minded fellow researchers. Free refreshments and snacks will be provided. Date 19 April 2018, 12 noon - 1:30 p.m. Venue Campus Bahrenfeld, CFEL, SR We founded Cellzome as an EMBL spin-off company to apply proteomics technologies to drug discovery, using all aspects of what we had learnt - from proteomics to hiring the best people no matter where they come from. I moved to industry because I was attracted by the thought of making something so useful that somebody would actually pay for it. Founding Cellzome offered a fantastic.
. mor A systematic search through human genes has begun at the European Molecular Biology Laboratory [EMBL] in Heidelberg, Germany. Working within the MitoCheck consortium that includes 10 other institutes throughout Europe, the EMBL scientists will silence all human genes, one-by-one, to find those involved in cell division [mitosis] and to answer fundamental questions of how cell division is. The first joint EMBL-VIB Alumni meeting will be hosted by VIB, on 24th October in Ghent, Zwijnaarde. This a great networking opportunity with a special focus on technology transfer and industry. Programme . Friday 24 October 2014, VIB. 13:30 14:00 14:30 15:30 16:30 17:00 18:00. Welcome coffee VIB and EMBL overview by Jo Bury, Managing Director and Iain Mattaj, EMBL Director General From.
Das Startup ist ein Spin-off des DKFZ und des NCT in Heidelberg. GetSafe. Versicherungen wieder attraktiv machen - das ist die Idee von Getsafe. Dazu denkt und entwickelt das InsurTech Startup Versicherungen komplett neu und setzt auf digitale Lösungen: Mit nur wenigen Klicks können die Kunden eine Versicherung bequem auf dem Smartphone abschließen. Unkompliziert, transparent, fair. Denn. Lange dachte man, dass bei der ersten embryonalen Zellteilung nur eine Spindel für die Auftrennung aller Chromosomen des Embryos in zwei Zellen verantwortlich ist. EMBL-Wissenschaftler zeigen nun, dass es tatsächlich aber zwei Spindeln gibt, eine für jeden elterlichen Chromosomensatz; das bedeutet, dass die genetischen Informationen von Mutter und Vater während der ersten Teilung getrennt. Velabs Therapeutics GmbH is a young spin-off of the EMBL (European Molecular Biology 3.7. Miltenyi Biotec B.V. & Co. KG. Program Manager - Medical Device Development in Biotechnology (m|w|d) Bergisch Gladbach. 1 Tg. You have already successfully demonstrated your product development skills in the field of medicine, pharmaceuticals or biotechnology over several years 4. PPD. START-UP.
An der Standortwahl von PixelBiotech zeigen sich die großen Vorteile der Helmholtz-Gemeinschaft: Das Spin-off des einen Helmholtz-Zentrums siedelt sich auf dem Campus des anderen Helmholtz-Zentrums an, um die dort bereits vorhandene Forschungsinfrastruktur zu nutzen. Das DESY bietet alle nötigen Forschungsanlagen zur Weiterentwicklung der Technologien. Viele weitere Start-ups der gleichen. ARAXA Biosciences was founded as a spin-off company from Europe's most prestigious life science research and instrumentation institute, the European Molecular Biology Laboratory (EMBL) in Heidelberg and its technology transfer arm EMBLEM Technology Transfer GmbH (EMBLEM). ARAXA aims to set new standards for the development of antibody-based therapeutics and diagnostics drug conjugates . For. Many translated example sentences containing embl Heidelberg - German-English dictionary and search engine for German translations
Nach Laboratory research associate-Jobs suchen. Finden Sie den richtigen Laboratory research associate-Job mit Bewertungen und Gehältern. 32 Jobs für Laboratory research associate The first joint EMBL-VIB Alumni meeting will be hosted by VIB, on 24th October in Ghent, Zwijnaarde. This a great networking opportunity with a special focus on technology transfer and industry. Programme. Friday 24 October 2014, VIB. 13:30 14:00 14:30 15:30 16:30 17:00 18:00. Welcome coffee VIB and EMBL overview by Jo Bury, Managing Director and Iain Mattaj, EMBL Director General From science. 16-Oct-2015 - European Molecular Biology Laboratory (EMBL) Lighting the way. Luxendo. The company's MuVi-SPIM microscopes - initially developed by Hufnagel at EMBL - are already available on the market. Zoom in ‹. EMBL in the Press; Publications; Members; Contact; Browse through Press Releases: For more information please contact the Press Office: Annika Grandison Tel: +49 6221 387-8443 Email. Mathias Jäger Tel: +49 6221 387-8726 Email. Press Releases. Heidelberg.
Finden Sie jetzt 24 zu besetzende Embl Jobs in Nußloch auf Indeed.com, der weltweiten Nr. 1 der Online-Jobbörsen. (Basierend auf Total Visits weltweit, Quelle: comScore GSK/Cellzome, a subsidiary of global healthcare company GlaxoSmithKline, and the European Molecular Biology Laboratory (EMBL) have signed a corporate partnership agreement whereby GSK will support the EMBL Advanced Training Centre in Heidelberg for three years with funding for conferences and training. In return, GSK will gain access to EMBL's state-of-the-art training facilities and may. Meyerhofstraße 1 69117 Heidelberg Germany Industry sector: Biotehnology Products/services: Fast screening of functional therapeutic antibodies Location(s): Heidelberg Date of foundation: 2017 Number of employees: 9 About the company/organisation: Velabs is a spin-off company founded by EMBL and EMBLEM and is currently hosted on EMBL's Campus area in Heidelberg The Nordic EMBL Partnership for Molecular Medicine is a unique network of excellent national research centers with complementary research expertise. The centers combine the longstanding tradition of basic and translational molecular medicine in the Nordic countries, with the research infrastructure, core principles and governance and operational models of the European Molecular Biology.
million in February 2001, specialized in proteomics and a spin-off from the prestigious EMBL research center in Heidelberg. ->Biolipox, a Swedish company specialized in the discovery and development of new therapeutic compounds for use in the treatment of respiratory diseases. Sofinnova Partners was the co-leader for the first financing round, which raised EUR 2.3 million in March 2001. By 2030, Austria shall have a flourishing spin-off ecosystem with a significant number of additional 1,000 new start-up companies. This will raise the GDP, create new jobs and opportunities for young people mobilising scientific talents in all areas. Statement of the Federal President of the Republic of Austria I welcome the Spin-off Austria Conference and its efforts to promote the. Martin served in various sales, marketing and R&D functions at Siemens AG before he became the CEO of Bruker AXS, a divested spin-off from Siemens in 1997. After the IPO of Bruker AXS (Nasdaq) he led the company through a public merger with Bruker Daltonics. After 10 years in the US he returned to Germany to become the managing director of Leica Microssystems GmbH. In 2007 he took over the.
EMBL Heidelberg, Researchers at the European Molecular Biology Laboratory (EMBL) in Grenoble, France, have determined the detailed 3-dim Previously he was board member and chief business officer of Polyneuron Pharmaceuticals, a spin-off company of the university of Basel. Before joining Polyneuron, he was founder, board member and CSO of GlycoVaxyn, a vaccine development company that was acquired by GSK in 2015 and which valued the company at $212 million. Michael co-founded GlycoVaxyn in 2004 as a spin-off company from the.
EMBL scientists are working with EMBL's spin-off company Savira pharmaceuticals, in partnership with Roche, to further develop influenza inhibitors. Promising candidates will be tested first for. Headquartered in Heidelberg, Germany, LUXENDO was founded in 2015 as a spin-off from the European Molecular Biology Laboratory (EMBL). LUXENDO's patented SPIM technology allowed the fast development of robust product solutions. Now part of Bruker Corporation, LUXENDO offers light-sheet microscopes enabling new research approaches in embryology, live-cell imaging, brain development, cleared. Search the world's information, including webpages, images, videos and more. Google has many special features to help you find exactly what you're looking for Nach Research associate biology-Jobs suchen. Finden Sie den richtigen Research associate biology-Job mit Bewertungen und Gehältern. 38 Jobs für Research associate biology
Cherry Biolabs ist ein Spin-off des Universitätsklinikums Würzburg. Das Unternehmen besitzt die exklusive Lizenz für die von der Universität Würzburg erteilte Hemibody-Plattformtechnologie. This is MuVi-SPIM, a light-sheet microscope developed at EMBL and commercialised by Luxendo To date, EMBL Venture Capital Partners has three companies in its portfolio, two of them spinouts from the EMBL. The first, Cenix BioScience GmbH, of Dresden, specializes in RNA interference technology. The second, which is not an EMBL spin-off, is febit AG, of Mannheim. The company is developing and manufacturing a benchtop microarray facility and aims for fully automated DNA analysis. The.
Nach Technical research assistant-Jobs suchen. Finden Sie den richtigen Technical research assistant-Job mit Bewertungen und Gehältern. 59 Jobs für Technical research assistant Nachrichten zum Thema 'Internationaler Preis an Dresdner Biotechnologen für bedeutende gentechnische Entwicklungen' lesen Sie kostenlos auf JuraForum.de About the team/job EMBL (European Molecular Biology Laboratory) is looking for a research associate to join the Genomics Core Facility (GeneCore) team at its main Laboratory in Heidelberg to participate in genomics projects carried out in collaboration with Cellzome/GSK located on campus. The selected candidate will work in the interdisciplinary environment connectin
Access to the culture of the host country/language courses Accommodation Banking Day care, schooling & family related issues Departure conditions/formalitie